CN103180315A - 治疗精神紊乱的方法 - Google Patents

治疗精神紊乱的方法 Download PDF

Info

Publication number
CN103180315A
CN103180315A CN2011800528248A CN201180052824A CN103180315A CN 103180315 A CN103180315 A CN 103180315A CN 2011800528248 A CN2011800528248 A CN 2011800528248A CN 201180052824 A CN201180052824 A CN 201180052824A CN 103180315 A CN103180315 A CN 103180315A
Authority
CN
China
Prior art keywords
lurasidone
adhd
pharmaceutically acceptable
acceptable acid
hyperactivity disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800528248A
Other languages
English (en)
Chinese (zh)
Inventor
池田和仁
石山健夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Co Ltd
Original Assignee
Sumitomo Dainippon Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46020227&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN103180315(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sumitomo Dainippon Pharma Co Ltd filed Critical Sumitomo Dainippon Pharma Co Ltd
Publication of CN103180315A publication Critical patent/CN103180315A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2011800528248A 2010-11-08 2011-05-24 治疗精神紊乱的方法 Pending CN103180315A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41108110P 2010-11-08 2010-11-08
US61/411081 2010-11-08
JP2011-033453 2011-02-18
JP2011033453 2011-02-18
PCT/JP2011/062314 WO2012063513A1 (en) 2010-11-08 2011-05-24 Method of treatment for mental disorders

Publications (1)

Publication Number Publication Date
CN103180315A true CN103180315A (zh) 2013-06-26

Family

ID=46020227

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800528248A Pending CN103180315A (zh) 2010-11-08 2011-05-24 治疗精神紊乱的方法

Country Status (6)

Country Link
US (5) US8258139B2 (https=)
EP (1) EP2638038A4 (https=)
JP (2) JP5855670B2 (https=)
CN (1) CN103180315A (https=)
CA (1) CA2814828C (https=)
WO (1) WO2012063513A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103565776A (zh) * 2012-07-25 2014-02-12 天津市汉康医药生物技术有限公司 一种稳定的鲁拉西酮胶囊药物组合物
WO2014192868A1 (ja) * 2013-05-30 2014-12-04 大日本住友製薬株式会社 環状アミノメチルピリミジン誘導体
US10272080B2 (en) 2013-09-13 2019-04-30 Florida State University Research Foundation, Inc. Selective dopamine D4 receptor agonists for treatment of working memory deficits
JP6594351B2 (ja) 2014-06-16 2019-10-23 ジョンソン、マッセイ、パブリック、リミテッド、カンパニー 新規中間体を含むアルキル化アリールピペラジン及びアルキル化アリールピペリジン化合物の製造方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1826338A (zh) * 2003-06-23 2006-08-30 大日本住友制药株式会社 老年性痴呆症治疗药

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2800953B2 (ja) 1990-07-06 1998-09-21 住友製薬株式会社 新規なイミド誘導体
DK36291D0 (da) 1991-03-01 1991-03-01 Lundbeck & Co As H Anvendelse af piperidylsubstituerede indolderivater til behandling af kognitive lidelser
GB9202915D0 (en) 1992-02-12 1992-03-25 Wellcome Found Chemical compounds
IL110011A (en) 1994-06-13 2004-09-27 Yeda Res & Dev Pharmacological preparations for the treatment of schizophrenia
WO1996014297A1 (en) 1994-11-04 1996-05-17 Sumitomo Pharmaceuticals Company, Limited Novel lactam derivatives
JP3775823B2 (ja) 1995-06-09 2006-05-17 大日本住友製薬株式会社 新規なイミド誘導体
US5688798A (en) * 1995-10-10 1997-11-18 Hoffmann-La Roche Inc. Pyrimidine compounds
EP1073432B1 (en) 1998-04-14 2007-08-15 The General Hospital Corporation Use of d-serine or d-alanine for treating schizophrenia
JP2000281576A (ja) 1999-03-29 2000-10-10 Sumitomo Pharmaceut Co Ltd イミド誘導体を含有するプロテオグリカン生成促進剤
AR027134A1 (es) 1999-12-30 2003-03-12 Lundbeck & Co As H Derivados de indol.
CA2422044A1 (en) 2000-09-14 2002-03-21 Gliatech, Inc. Nitrogen-containing compounds and their use as glycine transport inhibitors
JP4868695B2 (ja) 2000-09-22 2012-02-01 大日本住友製薬株式会社 崩壊性が良好な経口製剤
CA2431041A1 (en) 2001-01-02 2002-07-11 Pharmacia & Upjohn Company New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents
EP1395257A1 (en) 2001-06-12 2004-03-10 Elan Pharmaceuticals, Inc. Macrocycles useful in the treatment of alzheimer's disease
JP4568463B2 (ja) 2001-11-05 2010-10-27 独立行政法人科学技術振興機構 ドレブリンａ発現抑制動物神経細胞及び非ヒトモデル動物
JP4175800B2 (ja) 2001-11-27 2008-11-05 住友化学株式会社 イミド誘導体の製造方法
EP1480629A1 (en) 2002-02-08 2004-12-01 Abbott Laboratories Combination therapy for treatment of schizophrenia
EP1535616B1 (en) 2002-08-22 2009-05-13 Dainippon Sumitomo Pharma Co., Ltd. Remedy for integration dysfunction syndrome
US20070160537A1 (en) 2004-02-20 2007-07-12 Takeo Ishiyama In vivo screening method of therapeutic agent for memory/learning dysfunctions by schizophrenia
US7122683B2 (en) * 2004-11-23 2006-10-17 Pfizer Inc. Amides useful as monoamine re-uptake inhibitors
US8283352B2 (en) * 2005-06-13 2012-10-09 Dainippon Sumitomo Pharma Co., Ltd. Solubilization preparation
TW200812993A (en) 2006-05-02 2008-03-16 Lundbeck & Co As H New uses of escitalopram
CN101663308A (zh) 2006-10-30 2010-03-03 桑尔克斯药品公司 N-甲基色胺钙五水合物(dcp)和基于它的治疗方法
CA2682494C (en) * 2007-04-04 2011-10-11 Merck & Co., Inc. Hexahydro-1h-4,7-methanoisoindole-1,3-dione compounds for treating psychiatric disorders
JP2008135074A (ja) 2008-02-25 2008-06-12 Fujitsu Ltd 情報公開方法および情報公開装置

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1826338A (zh) * 2003-06-23 2006-08-30 大日本住友制药株式会社 老年性痴呆症治疗药

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
POWELL S.B.等: "RO-10-5824 is a selective dopamine D4 receptor agonist that increases novel object exploration in C57 mice", 《NEUROPHARMACOLOGY》 *

Also Published As

Publication number Publication date
US20190022091A1 (en) 2019-01-24
US9827242B2 (en) 2017-11-28
JP6470164B2 (ja) 2019-02-13
US20120115879A1 (en) 2012-05-10
US8258139B2 (en) 2012-09-04
CA2814828C (en) 2019-09-10
US20160129000A1 (en) 2016-05-12
JP2013541582A (ja) 2013-11-14
US20160193205A1 (en) 2016-07-07
JP2016094440A (ja) 2016-05-26
US10098875B2 (en) 2018-10-16
US9259423B2 (en) 2016-02-16
US20130018056A1 (en) 2013-01-17
EP2638038A1 (en) 2013-09-18
CA2814828A1 (en) 2012-05-18
JP5855670B2 (ja) 2016-02-09
EP2638038A4 (en) 2014-03-12
WO2012063513A1 (en) 2012-05-18

Similar Documents

Publication Publication Date Title
JP2010510314A (ja) 精神遅滞、ダウン症候群、脆弱ｘ症候群および自閉症の治療方法
JP2010507672A (ja) アルツハイマー病を治療するための方法および組み合わせ治療
US11826321B2 (en) Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
JP6196239B2 (ja) 精神及び行動の障害治療剤
US20190022091A1 (en) Method of treatment for mental disorders
TWI387452B (zh) 用於治療性功能障礙之方法
RU2686110C1 (ru) Производное хромона в качестве антагониста дофаминового рецептора d3 для применения при лечении расстройства аутистического спектра
CN105764510A (zh) H3受体拮抗剂与胆碱酶抑制剂组合用于阿尔茨海默氏病治疗中的用途
CN116075302A (zh) GABAAα5激动剂和SV2A抑制剂的组合以及在认知损害的治疗中的使用方法
WO2019161179A1 (en) Methods of treating developmental syndromes with pde10a inhibitors
US20240252478A1 (en) Benzodioxane Modulators of Leukotriene A4 Hydrolase (LTA4H) for Prevention and Treatment of Aging-Associated Diseases
JP2022554090A (ja) 自閉症スペクトラム障害の症状を治療する方法
JP5299949B2 (ja) シロスタゾールの統合失調症治療剤
JP2014507370A (ja) 特定のα−７ニコチン酸受容体アゴニストを、アセチルコリンエステラーゼ阻害剤と組み合わせて、用いた認知障害の処置
JP2012102069A (ja) 早漏治療剤
HK40092010A (zh) GABAAα5激动剂和SV2A抑制剂的组合以及在认知损害的治疗中的使用方法
WO2012168411A1 (fr) Utilisation de la carpipramine dans le traitement de troubles psychiatriques et du developpement chez l'enfant et l'adolescent
Hohnadel et al. CHRONIC HALOPERIDOL AND RISPERIDONE TREATMENT DISRUPT ACQUISTION IN A TEST OF SUSTAINED ATTENTION IN RATS WITHOUT ALTERATION OF VACHT AND A7NACHR LEVELS IN MEDIAL PREFRONTAL CORTEX

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130626